Resumen

RIOJA, Patricia et al. Latest advances in neoadjuvant therapy for bladder cancer. Acta méd. Peru [online]. 2022, vol.39, n.1, pp.59-64.  Epub 05-Ene-2022. ISSN 1728-5917.  http://dx.doi.org/10.35663/amp.2022.391.2201.

Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations from international and/or local practice guidelines, as well as studies of new therapeutic agents (immunotherapy, targeted therapy), on top of research on potential biomarkers that may predict response to immunotherapy.

Palabras clave : Urinary Bladder Neoplasms; Neoadjuvant Therapy; Immunotherapy; Biomarkers.

        · resumen en Español     · texto en Español     · Español ( pdf )